Memantine Hydrochloride Solution
Product Images NDC 13925-540

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 13925-540). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Seton Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 Memantine (Figure 1 Memantine)

The text describes a chart showing the mean change from baseline in ADCS-ADL score, indicating clinical improvement or decline, with SEM data. Results are shown for both a placebo and memantine treatment group over a two-week treatment period.*

FDA Label Image

Figure 2 Memantine (Figure 2 Memantine)

FDA Label Image

Figure 3 Memantine (Figure 3 Memantine)

FDA Label Image

Figure 4 Memantine (Figure 4 Memantine)

FDA Label Image

Figure 5 Memantine (Figure 5 Memantine)

FDA Label Image

Figure 6 Memantine (Figure 6 Memantine)

FDA Label Image

Figure 7 Memantine (Figure 7 Memantine)

FDA Label Image

Figure 8 Memantine (Figure 8 Memantine)

FDA Label Image

Memantine Instructions (Instructions)

Instructions for using a syringe and plastic bottle adapter to administer Memantine Hydrochloride Oral Solution. The guidelines include removing the adapter from its protective plastic bag and inserting it properly into the neck of the bottle, filling the syringe with the prescribed dosage, administering the solution to the patient orally, and ensuring proper cleaning and storage of the syringe and adapter. Detailed figures are provided to assist with the steps.*

FDA Label Image

Memantine Bottle (Memantine Bottle)

FDA Label Image

Table 1 (Table 1)

This appears to be a chart comparing the percentage of adverse reactions between a placebo group and a group using memantine hydrochloride. The adverse reactions listed include fatigue, pain, hypertension, dizziness, headache, constipation, vomiting, back pain, confusion, somnolence, hallucination, coughing, and dyspnea. The percentages vary between the two groups, with some reactions being higher in the group using memantine hydrochloride and some being higher in the placebo group.*

FDA Label Image

Dosing-titration-schedule (Dosing Titration Schedule)

This appears to be a medication dosing chart displaying the total daily dose as well as the strength per dose in milligrams. The dosing increases over the course of three weeks with specific amounts listed for the first and second daily doses.*

FDA Label Image

Label (Label)

This is a description of a medication, Memantine Hydrochloride Oral Solution, available only with a prescription, containing 2 mg of memantine hydrochloride in each mL of solution. The bottle contains 12 fl oz (360 mL) of solution and has a tamper-evident seal. It should be kept out of reach of children and stored at a temperature between 15-30°C (59-86°F). The dosage information can be found in the package insert. The medication is manufactured by Wedly Pharmaceuticals Ltd. in India and Seton Pharmaceuticals in Wall, NJ, USA. The lot number and expiration date are not available.*

FDA Label Image

Memantine-structure (Memantine Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.